Open-label Extension Study of Brazikumab in Crohn's Disease

Stopped Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.

Conditions

• Crohn's Disease
• IBD

Interventions

• DRUG: Brazikumab Induction Dose
• DRUG: Brazikumab Maintenance Dose

Sponsor

AstraZeneca